Close

Form 8-K IMMUNOMEDICS INC For: Dec 16

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/19/2024

1. NFLX
2. TSM
3. ISRG
4. SPY
5. INFY
6. SNV
7. TSLA
8. SMCI
9. SLB
10. PPG


December 17, 2014 4:31 PM EST
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
�
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
�
�
Date of report (Date of earliest event reported): December 16, 2014
�
Immunomedics, Inc.
(Exact Name of Registrant as Specified in Charter)

�Delaware 000-12104 61-1009366
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)

300 The American Road, Morris Plains, New Jersey 07950
(Address of Principal Executive Offices)
(Zip Code)

(973) 605-8200
(Registrant's telephone number,
including area code)
�
�
___________________Not applicable_____________________
(Former Name or Former Address, if Changed Since Last Report)
�
Check the appropriate box below if the Form�8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
�
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
�
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
�
o
Pre-commencement communications pursuant to Rule�14d-2(b) under the Exchange Act (17�CFR 240.14d-2(b)).
�
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
�
�
�
�
Item 8.01.����Other Events
�
On October 3, 2013, Takeda Pharmaceutical Company Limited, the parent company of Nycomed GmbH (Takeda-Nycomed), delivered notice of termination of its worldwide licensing agreement (the Agreement) with Immunomedics, Inc. (the Company) to develop, manufacture and commercialize veltuzumab for the treatment of all non-cancer indications.��Takeda-Nycomed terminated the Agreement subsequent to the Companys filing of arbitration proceedings concerning delays in Takeda-Nycomeds development of veltuzumab, which the Company argued was a material breach of the Agreement.��In response to the Companys claim for damages for the delays, Takeda-Nycomed made certain counterclaims against the Company.

On December 16, 2014, the Company was notified that the arbitrator awarded no money to either party and the award was in full settlement of all claims and counterclaims submitted to arbitration.��All rights to veltuzumab have reverted back to the Company as a result of the termination.
�
�
�

�
�
�
�
SIGNATURES
�
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
�
� � IMMUNOMEDICS, INC.
� �
�
�
�
� � By: /s/ Cynthia L. Sullivan
� � � Name: Cynthia L. Sullivan
� � � Title: President and Chief Executive Officer
�
�
Date:��December 17, 2014
�
�
�
�
�

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings